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Reduction of the LVOT gradient post PTSMA was determined by echocardiographic. 
Results: All patients demonstrated regional myocardial hyperenhancement of the inter- 
ventricular septum, exclusively located on the right ventricular side of the septum in 7. In 
patients with exclusively right sided hyperenhancement, the LVOT gradient reduction 
was 3Oi 28 mmHg versus 78* 22 mmHg in the remaining patients (p<O.OOl). Myocardial 
injury size in the right sided group was significantly lower (lo+ 4 g vs. 23+ 8 g, pcO.001). 
In these patients the volume of ethanolinjected was lower (2.6* 1.2 ml versus 3.6* 1.8 
ml, p = 0.19) and the ethanol was infused distal of a bi- or trifurcation in 4 out of 7 
patients. In the remaining patients ethanol was injected proximally in the septal branch. 
Conclusion: In patients with HOCM, size and location of myocardial injury induced by 
PTSMA can be determined using contrast-enhanced MRI. An exclusively right sided 
locatlon of myocardial injury is associated with lesser reduction of the LVOT gradient. 
1014-86 Progressive Left Ventricular Impairment in 
Hypertrophic Cardiomyopathy Patients Is Determined 
by Functional Location of Mutation 
Saidi A. Mohiddin, Judy Wlnkler. Dorothy Tripodi, Dorothea McAreavey, Lameh 
Fananapazir, National Heart Lung and Blood Institute, Bethesda, MD 
Background: More than 70 mutations affecting emyosin heavy chain (P-MHC coded by 
MYH7j, the commonest cause of familial hypetitophic cardiomyopathy (FHC), are 
reported. Mutation-specific natural history contributes to patient management, but most 
mutations are uncharacterized. We sought to determine if the affected functional domain 
Influences outcome, allowing domain-specific prognosis. Several MYH7 mutations affect 
the converter (CD), whlch@nctions as a fulcrum for force leverage. Methods: Residues 
of the CD were predicted from FMHC’s 3-D structure. Echo and clinical date from unre- 
lated FHC patients with a CD mutation (CD+) were compared with 98 unrelated patients 
without CD mutations (CD-), a subset of whom had other MYH7mutations. Results: 
There were 9 CD mutations in 22 pattents. Compared to all CD- patients, CD+ patients 
were diagnosed with FHC at younger age (22210 vs 35il8 years, p<O.OOl) and more 
frequently had a family history of HCM (15/22 vs 42/98, ~~0.05). Magnitude of left ven- 
tricular (LV) hypertrophy and LV gradients were similar. CD+ patients had lower frac- 
tional shortening (FS; 36214 vs 42+7, pcO.005) despite a lower mean age (34214 vs 
47218 years, pcO.005). FS was ~30% in 7121 CD+ patients and only 4/83 CD- patients, 
pcO.001. CD+ patients with FS<30 were older than those with FS>30 (43+9 vs 30+14 
years, p<O.O5). MYH7mutations other than CD were found in 17/98 CD- patients; FHC 
was diagnosed at a younger age in CD+ patients (22tlO vs 31~17 years, p<O.O5), left 
atrial (LA) size was smaller (45&10 mm vs 54210; P=O.Ol) and FS lower (4227 vs. 4727, 
p=O.Ol) compared to patients with non-CD MYH7 mutations. Conclusions: Despite simi- 
lar magnitude of LV hypertrophy and LV obstruction. there are differences between FHC 
associated with CD mutations. non CD MYH7 mutations and non-MYH7causes. (1) CD 
mutations result in higher penetrance and presentation at a younger age; (2) CD muta- 
tlons are more likely to cause progressive LV systolic dysfunction; (3) LA distension 
associated with non CD MYH7 mutations may reflect greater diastolic dysfunction. Identi- 
fication of mutant functional domain will contribute to the management of FHC patients 
with MYH7 mutations of undetermined natural history. 
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Background: Hypertrophic cardiomyopathy (HCM) I” the young is associated with 
increased risk for sudden death (SD). We determined outcomes in a cohort of children 
attending a tertiary referral center, and prognostic significance of the presenting clinical 
findings. METHODS: Study comprised of 260 children aged <20 years (mean, lOr6 
years) with HCM: 13 (5%) presented with cardiac arrest, 52 (20%) had syncope, 34 
(13%) had presyncope. 91 (35%) had chest pain, 84 (32%) had dyspnea, and 80(31%) 
were asymptomatic. Studies included echocardiography, Halter, treadmIll exercise test, 
exercise thallium scintigraphy, cardiac catheterization, and electrophysiology study 
(EPS). Results: 240 children, or 92%, had one or more risks for SD, Table. Therapy 
included implantable defibrillators (ICD) in 56, pacemakers in 97, cardiac surgery for 
obstructtve HCM in 22, and cardiac transplantation in 6 (3 died post-operatively). Thirty- 
five adverse events: 20 deaths (13 SD); 8 cardiac arrests; and 7 ICD therapies. The 5- 
year sun/ival rate was 92+2%,and the 5.year event-free rate was 87+2%. Conclusions: 
(1) Traditional risk factors are common in young patients who presented to a tertiary 
referral center, and therefore as a group, have a poor predictive value. (2) Despite this 
high prevalence of risk factors associated wtth increased risk for SD, therapy directed at 
relieving symptoms and correcting identified abnormalities was associated with a prog- 
nosis similar to that reported from non-tertiary centers. 
Risk factors assocmted wth poor prognosis 
Parameter Prevalence 
Cardiac arrest or syncope 65/260(25%) 
LV outflow obstruction (cardiac cath) 11 O/210 (52%) 
LV wall thickness 320 mm 132/260(51%) 
Non-sustained ventricular tachycardia VT during 24-48 hr Halter 431234 (18%) 
Myocardial ischemia by exercise thallium 135/175(77%) 
Abnormal BP response to exercise 741224 (33%) 
Family History of sudden death 72/230 (31%) 
Genetic mutation associated with poor prognosis 20/48 (42%) 
Sustained ventricular tachycardia induced at EPS 371139 (27%) 
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Background: About 10% of cases of hypertrophic cardiomyopathy (HCM) develop a 
dilated cardiomyopathy (DCM). The molecular mechanisms of this evolution are still 
unknown. The genes accounting for approximately 2/3 of all HCM cases are O-myosin 
heavy chain (MyH7), myosin-binding protein C (MyBPC) and cardiac troponin T (cTnT). 
In order to investigate if specific gene mutations are consistently associated with HCM 
progressing to DCM we have performed mutational analysis of these genes in 10 unre- 
lated affected patients (pts). 
Methods: We enrolled 10 unrelated pts with HCM who progressed to DCM. symptomatic 
and with left ventricular dilatation and impaired contractile function but no ouflow tract 
gradient. Mutational analysis was performed for the entire coding region and exon-intron 
boundaries of the MyH7, MyBPC and cTnT genes using direct sequencing. 
Results: In these 3 genes a total of 5 missense mutations were found in 5 pts; 2 of these 
were previously described mutations and 3 were new mutations. The already known 
mutations were a MyH7 mutation (R453C) affecting the actin binding property and a vari- 
ation in the cTnT gene (K236R). The first new MyH7 mutation (L517M) occurred in the 
head-rod junction of myosin, lying close to a reactive cyst&e (Cys-695). The second 
MyH7 mutation (Q734E) occurred in the light chain-binding site following the reactive 
cysteines. A new MyBPC mutation (S236G) was found in the IG-kke C2-type domain 1 of 
the protein and is likely to disrupt the phosphorylation site. The simultaneous presence of 
two missense mutations in two different genes was observed in two pts, one carrying the 
newly discovered MyH7 (L517M) and MyBPC mutations and one carrying the MyBPC 
and the cTnT mutations. 
Conclusion: We identified 3 formerly unreported mutations and the simultaneous pres- 
ence of mutations I” two different genes in 2 pts. However we failed to identify a specific 
mutation in our pts with HCM who progressed to DCM. Thus the actlon of multiple gene 
mutations, the presence of modifier genes and post-transcriptional mechanisms appear 
to play a major role in the progression from HCM to DCM. 
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1038-68 Left Ventricular Systolic Function and Survival in a 
Contemporary Cohort of Patients With Heart Failure 
Frederick A. Masoudi, Pam wore, Saif S. Rathore. Joanne M. Foody, Diana L. Ordin, 
Harlan M. Krumholz. Edward P. Havranek. Denver Health Medical Center, Denver, CO, 
Colorado Foundation for Medical Care, Aurora, CO 
Background: Although preserved left ventricular systolic function (LVSF) reportedly con- 
fers a better prognosis than impaired LVSF in patients with heart failure, it is unclear if 
this pattern exists in current practice. Our goal was to describe the independent relation- 
ship between LVSF and survival in a cohort of patients with heart failure. 
Methods: We used data from the CMS-sponsored National Heart Failure (NHF) Project, 
a national sample of Medicare beneficiaries hospitalized with a principal diagnosis of 
heart failure in 1998 and 1999. We studied patients at least 65 years old who were dis- 
charged alive (n=31,991). Multivariable Cox proportional hazards regression with mean 
follow-up of one year was employed, adjusting for patlent factors and differences in ACE- 
inhibitor prescription at discharge. 
Results: Crude mortality rates and fully adjusted hazard ratios for mortality among ACE- 
treated and non-ACE-treated patients are presented below. In the multivariable model, 
there was a graded inverse relationship between LVSF and mortality. Although ACE- 
